@article{3220155,
    title = "COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations",
    author = "Jutel, M. and Torres, M.J. and Palomares, O. and Akdis, C.A. and Eiwegger, T. and Untersmayr, E. and Barber, D. and Zemelka-Wiacek, M. and Kosowska, A. and Palmer, E. and Vieths, S. and Mahler, V. and Canonica, W.G. and Nadeau, K. and Shamji, M.H. and Agache, I. and Akdis, M. and Khaitov, M. and Alvarez-Perea, A. and Alvaro-Lozano, M. and Atanaskovic-Markovic, M. and Backer, V. and Barbaud, A. and Bavbek, S. and de Blay, F. and Bonini, M. and Bonini, S. and van Boven, J.F.M. and Brockow, K. and Cazzola, M. and Chatzipetrou, A. and Chivato, T. and Cianferoni, A. and Corren, J. and Cristoph-Caubet, J. and Dunn-Galvin, A. and Ebisawa, M. and Firinu, D. and Gawlik, R. and Gelincik, A. and del Giacco, S. and Mortz, C.G. and Jürgen Hoffmann, H. and Hoffmann-Sommergruber, K. and Klimek, L. and Knol, E. and Lauerma, A. and de Llano, L.P. and Matucci, A. and Meyer, R. and Moreira, A. and Morita, H. and Patil, S.U. and Pfaar, O. and Popescu, F.-D. and del Pozo, V. and Price, O.J. and van Ree, R. and Fernández-Rivas, M. and Rogala, B. and Romano, A. and Santos, A. and Sediva, A. and Skypala, I. and Smolinska, S. and Sokolowska, M. and Sturm, G. and Vultaggio, A. and Walusiak-Skorupa, J. and Worm, M.",
    journal = "Allergy: European Journal of Allergy and Clinical Immunology",
    year = "2022",
    publisher = "John Wiley and Sons Inc",
    doi = "10.1111/all.15252",
    abstract = "Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)-5 and IL-4/IL-13 or non-type 2 response: anti-cytokine antibodies and B-cell depletion via anti-CD20. Coronavirus disease 2019 (COVID-19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals. © 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd."
}